Germano Lucci
Parma, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Pharmacokinetic profile of beclometasone dipropionate/formoterol fumarate administered through a novel dry-powder inhaler in Chinese healthy volunteers.
Journal: Pulmonary pharmacology & therapeutics
Published: May 11, 2021
COPD patients with chronic bronchitis and higher sputum eosinophil counts show increased type-2 and PDE4 gene expression in sputum.
Journal: Journal of cellular and molecular medicine
Published: September 26, 2020
COPD sputum eosinophils: relationship to blood eosinophils and the effect of inhaled PDE4 inhibition.
Journal: The European respiratory journal
Published: February 04, 2020
Sputum and blood transcriptomics characterisation of the inhaled PDE4 inhibitor CHF6001 on top of triple therapy in patients with chronic bronchitis.
Journal: Respiratory research
Published: October 17, 2019
Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD.
Journal: Respiratory research
Published: June 12, 2019
Safety, tolerability, and pharmacokinetics of single and repeat ascending doses of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor: two randomized trials in healthy volunteers.
Journal: International journal of chronic obstructive pulmonary disease
Published: November 15, 2018
Pharmacokinetics and pharmacodynamics of an extrafine fixed pMDI combination of beclometasone dipropionate/formoterol fumarate in adolescent asthma.
Journal: British journal of clinical pharmacology
Published: December 12, 2014
The systemic exposure to inhaled beclometasone/formoterol pMDI with valved holding chamber is independent of age and body size.
Journal: Pulmonary pharmacology & therapeutics
Published: January 28, 2014
Showing 1-9 of 9
Last Updated: 09/26/2026